BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35546353)

  • 21. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1.
    Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F
    J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. General mechanism of JQ1 in inhibiting various types of cancer.
    Jiang G; Deng W; Liu Y; Wang C
    Mol Med Rep; 2020 Mar; 21(3):1021-1034. PubMed ID: 31922235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Epigenetic Compound Library Screen Identifies BET Inhibitors That Promote HSV-1 and -2 Replication by Bridging P-TEFb to Viral Gene Promoters through BRD4.
    Ren K; Zhang W; Chen X; Ma Y; Dai Y; Fan Y; Hou Y; Tan RX; Li E
    PLoS Pathog; 2016 Oct; 12(10):e1005950. PubMed ID: 27764245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long non-coding RNA MANCR is a target of BET bromodomain protein BRD4 and plays a critical role in cellular migration and invasion abilities of prostate cancer.
    Nagasawa M; Tomimatsu K; Terada K; Kondo K; Miyazaki K; Miyazaki M; Motooka D; Okuzaki D; Yoshida T; Kageyama S; Kawamoto H; Kawauchi A; Agata Y
    Biochem Biophys Res Commun; 2020 May; 526(1):128-134. PubMed ID: 32199616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway.
    Wen N; Guo B; Zheng H; Xu L; Liang H; Wang Q; Wang D; Chen X; Zhang S; Li Y; Zhang L
    Int J Oncol; 2019 Oct; 55(4):879-895. PubMed ID: 31485609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1.
    Decker TM; Kluge M; Krebs S; Shah N; Blum H; Friedel CC; Eick D
    Sci Rep; 2017 May; 7(1):1684. PubMed ID: 28490802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
    Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
    Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling.
    Wu X; Qi J; Bradner JE; Xiao G; Chen LF
    J Biol Chem; 2013 Dec; 288(50):36094-105. PubMed ID: 24189064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
    Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T
    Oncotarget; 2016 Nov; 7(48):79217-79232. PubMed ID: 27764794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
    Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
    Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of BRD4 triggers cellular senescence through suppressing aurora kinases in oesophageal cancer cells.
    Xu JL; Yuan YJ; Lv J; Qi D; Wu MD; Lan J; Liu SN; Yang Y; Zhai J; Jiang HM
    J Cell Mol Med; 2020 Nov; 24(22):13036-13045. PubMed ID: 32954665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MCM5 as a target of BET inhibitors in thyroid cancer cells.
    Mio C; Lavarone E; Conzatti K; Baldan F; Toffoletto B; Puppin C; Filetti S; Durante C; Russo D; Orlacchio A; Di Cristofano A; Di Loreto C; Damante G
    Endocr Relat Cancer; 2016 Apr; 23(4):335-47. PubMed ID: 26911376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells.
    Baek M; Chai JC; Choi HI; Yoo E; Binas B; Lee YS; Jung KH; Chai YG
    PLoS One; 2022; 17(4):e0266966. PubMed ID: 35486664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
    Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
    Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long Non-Coding RNA MALAT1 Regulates ZEB1 Expression by Sponging miR-143-3p and Promotes Hepatocellular Carcinoma Progression.
    Chen L; Yao H; Wang K; Liu X
    J Cell Biochem; 2017 Dec; 118(12):4836-4843. PubMed ID: 28543721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
    Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
    Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1.
    Horne GA; Stewart HJ; Dickson J; Knapp S; Ramsahoye B; Chevassut T
    Stem Cells Dev; 2015 Apr; 24(7):879-91. PubMed ID: 25393219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
    Blee AM; Liu S; Wang L; Huang H
    Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.